new glp 1 receptor agonists GLP-1 as Treatments for Type 2 Diabetes GLP-1 Receptor Agonist Services for

The new class of weight-loss medications are hailed as game-changing wonder drugs, but just how safe and effective are they

In November 2025, the Trump administration announced landmark agreements with Eli Lilly and Novo Nordisk reducing the monthly price of GLP-1 weight-loss drugs from over $1,000 to as low as $245 for eligible patients

Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information for healthcare providers.

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials